NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28
NanoString Technologies has announced the launch of its CosMx Spatial Molecular Imager (SMI), a spatial multi-omics platform allowing for advanced protein and RNA expression analysis at single-cell resolution. This unveiling will take place at the Spatial Genomics Summit on February 28, 2022. The CosMx SMI can analyze up to 1,000 RNA and 100 protein analytes from intact tissue samples, enhancing both discovery and translational research. The company also introduced a Spatial Pioneer Program for early access to this technology.
- Launch of the CosMx Spatial Molecular Imager, enhancing protein and RNA analysis capabilities.
- Ability to analyze up to 1,000 RNA and 100 protein analytes, facilitating advanced research.
- Initiation of the Spatial Pioneer Program providing early access to the new instrument.
- None.
CosMx SMI is the first spatial multi-omics platform with demonstrated protein and RNA expression analysis capabilities at single-cell and subcellular resolution
CosMx SMI is a spatial multi-omics solution enabling rapid quantification and visualization of up to 1,000 RNA and 100 validated protein analytes at single-cell and subcellular resolution of intact Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen tissue samples. With a tunable workflow from high-plex to high-throughput, CosMx enables discovery research by providing high-plex and unbiased whole-slide analysis, as well as translational research with low-plex, high-throughput biology-driven analysis. CosMx SMI is a complete sample-to-result in situ analysis platform with integrated cloud-based data analysis and visualization software.
In addition to the platform unveiling,
New approaches to interrogating underlying biology are required to understand complex disease, which is why
Spatial Genomics Summit Agenda
Spatial Genomics Applications: From basic discovery to clinical research
-
Clinical Biomarkers in Triple Negative Breast Cancer: The high-plex single-cell spatial revolution:
Jodi Carter , M.D., Ph.D.,Mayo Clinic -
Spatial single-cell characterization of SIV reservoirs in NHP lymphoid tissues:
Jacob Estes , Ph.D.,Oregon Health & Science University -
The Repeatome Shaping the Microenvironment of Pancreatic Cancer:
David Ting , M.D.,Mass General Hospital -
Panel discussion moderated by
Stephane Budel , Ph.D., DeciBio
Spatial Informatics Tools & Integration of Public Datasets
-
Spatial Informatics, Spatial AI and Public Datasets:
Joachim Schmid , Ph.D.,NanoString Technologies -
Panel discussion with
Christopher Mason , Ph.D., Weil Cornell;Ruben Dries , Ph.D.,Boston University ;Kevan Samiee , Ph.D., Illumina;Margaret Hoang , Ph.D.,NanoString Technologies ; andJason Reeves , Ph.D.,NanoString Technologies .
“We believe spatial biology will drive some of the most significant breakthroughs in health research, and we’re honored to bring together experts to showcase a variety of emerging spatial technologies and techniques,” said
To register for the Spatial Genomics Summit, visit https://www.nanostring.com/about-us/events/spatial-genomics-summit-2022/.
The CosMx SMI system is expected to be available for beta instrument placements in the second quarter of 2022, followed by a full commercial launch in late 2022. To learn more about NanoString’s CosMx Spatial Molecular Imager, visit www.nanostring.com/CosMx.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005206/en/
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Source:
FAQ
What is the CosMx Spatial Molecular Imager launched by NSTG?
When will NanoString Technologies unveil CosMx SMI?
How many analytes can the CosMx SMI analyze?